达雷妥尤单抗在T细胞急性淋巴细胞白血病中的临床前疗效
复发或难治性T细胞急性淋巴细胞白血病(T-ALL)预后极差,亟需低毒新药。研究发现T-ALL患者原始细胞表面CD38高表达且经多药化疗后稳定,达雷妥尤单抗在15例T-ALL患者来源异种移植(PDX)模型中的14例显示出显著疗效,提示其可能成为儿童T-ALL有前景的新疗法。
要点
- T-ALL患者原始细胞表面CD38高表达,多药化疗后表达稳定。
- CD38在正常淋巴、髓系及少数非造血组织低表达,或为理想靶点。
- 达雷妥尤单抗在15例T-ALL PDX中14例显示显著疗效。
核心结论
- 达雷妥尤单抗在T-ALL的PDX模型中显示显著疗效,提示其可能成为儿童T-ALL患者有前景的新疗法。
研究设计与样本
- 临床前研究:在15例T-ALL患者来源异种移植(PDX)模型中测试达雷妥尤单抗的疗效。
主要发现
- T-ALL患者原始细胞表面CD38强表达,且经多药化疗后表达保持稳定。
- CD38在正常淋巴和髓系细胞及少数非造血组织上表达水平极低。
- 达雷妥尤单抗在15例不同PDX模型中的14例显示出显著疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As a consequence of acquired or intrinsic disease resistance, the prognosis for patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) is dismal. Novel, less toxic drugs are clearly needed. One of the most promising emerging therapeutic strategies for cancer treatment is targeted immunotherapy. Immune therapies have improved outcomes for patients with other hematologic malignancies including B-cell ALL; however no immune therapy has been successfully developed for T-ALL. We hypothesize targeting CD38 will be effective against T-ALL. We demonstrate that blasts from patients with T-ALL have robust surface CD38 surface expression and that this expression remains stable after exposure to multiagent chemotherapy. CD38 is expressed at very low levels on normal lymphoid and myeloid cells and on a few tissues of nonhematopoietic origin, suggesting that CD38 may be an ideal target. Daratumumab is a human immunoglobulin G1κ monoclonal antibody that binds CD38, and has been demonstrated to be safe and effective in patients with refractory multiple myeloma. We tested daratumumab in a large panel of T-ALL patient-derived xenografts (PDX) and found striking efficacy in 14 of 15 different PDX. These data suggest that daratumumab is a promising novel therapy for pediatric T-ALL patients.
引用
- Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018. PMID: 29305553. doi:10.1182/blood-2017-07-794214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。